share_log

Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Acquires $412,000.00 in Stock

Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Acquires $412,000.00 in Stock

内部收购:Opko Health,Inc.(纳斯达克代码:OPK)首席执行官收购412,000.00美元股票
kopsource ·  2022/09/19 04:52

OPKO Health, Inc. (NASDAQ:OPK – Get Rating) CEO Phillip Md Et Al Frost purchased 200,000 shares of the firm's stock in a transaction dated Thursday, September 15th. The shares were bought at an average cost of $2.06 per share, with a total value of $412,000.00. Following the purchase, the chief executive officer now directly owns 197,456,694 shares of the company's stock, valued at approximately $406,760,789.64. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

奥普科健康公司(纳斯达克代码:OPK-GET Rating)首席执行官菲利普·马德等·弗罗斯特在9月15日星期四的交易中购买了该公司20万股股票。这些股票是以每股2.06美元的平均成本购买的,总价值为412,000.00美元。收购后,首席执行官现在直接拥有197,456,694股公司股票,价值约406,760,789.64美元。此次收购是在提交给美国证券交易委员会的一份法律文件中披露的,可以通过以下链接访问该文件。

Phillip Md Et Al Frost also recently made the following trade(s):

菲利普·马德和阿尔·弗罗斯特最近还进行了以下交易:

Get
到达
OPKO Health
Opko Health
alerts:
警报:
  • On Wednesday, August 17th, Phillip Md Et Al Frost acquired 200,000 shares of OPKO Health stock. The shares were acquired at an average cost of $2.54 per share, for a total transaction of $508,000.00.
  • On Friday, August 5th, Phillip Md Et Al Frost acquired 350,000 shares of OPKO Health stock. The shares were acquired at an average cost of $2.29 per share, for a total transaction of $801,500.00.
  • On Tuesday, June 21st, Phillip Md Et Al Frost acquired 200,000 shares of OPKO Health stock. The shares were acquired at an average cost of $2.39 per share, for a total transaction of $478,000.00.
  • 8月17日,星期三,Phillip Md et Al Frost收购了OPKO Health的20万股股票。这些股票是以每股2.54美元的平均成本收购的,总交易额为508,000.00美元。
  • 8月5日,星期五,Phillip Md et Al Frost收购了OPKO Health的350,000股股票。这些股票是以每股2.29美元的平均成本收购的,总交易额为801,500.00美元。
  • 6月21日,星期二,Phillip Md et Al Frost收购了OPKO Health的20万股股票。这些股票是以每股2.39美元的平均成本收购的,总交易额为478,000.00美元。

OPKO Health Price Performance

Opko健康性价比

NASDAQ OPK opened at $2.05 on Monday. The firm's fifty day simple moving average is $2.42 and its two-hundred day simple moving average is $2.81. The company has a current ratio of 2.30, a quick ratio of 1.91 and a debt-to-equity ratio of 0.12. OPKO Health, Inc. has a 12-month low of $1.96 and a 12-month high of $5.25. The firm has a market capitalization of $1.58 billion, a P/E ratio of -7.07 and a beta of 1.75.

纳斯达克OPK周一开盘报2.05美元。该公司的50日简单移动均线切入位为2.42美元,200日简单移动均线切入位为2.81美元。该公司的流动比率为2.30,速动比率为1.91,债务权益比率为0.12。Opko Health,Inc.的12个月低点为1.96美元,12个月高位为5.25美元。该公司的市值为15.8亿美元,市盈率为-7.07,贝塔系数为1.75。

OPKO Health (NASDAQ:OPK – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). OPKO Health had a negative return on equity of 7.72% and a negative net margin of 14.18%. The firm had revenue of $309.90 million during the quarter, compared to analysts' expectations of $326.87 million. During the same period in the prior year, the firm posted ($0.03) earnings per share. OPKO Health's revenue for the quarter was down 30.0% compared to the same quarter last year. Analysts forecast that OPKO Health, Inc. will post -0.38 EPS for the current fiscal year.
奥普科健康(纳斯达克代码:OPK-GET Rating)最近一次发布季度收益报告是在8月4日(星期四)。这家生物技术公司公布了该季度每股收益(EPS)(0.04美元),低于(0.02美元)的普遍预期。Opko Health的股本回报率为负7.72%,净利润率为负14.18%。该公司本季度营收为3.099亿美元,高于分析师预期的3.2687亿美元。去年同期,该公司公布的每股收益为0.03美元。与去年同期相比,Opko Health本季度的收入下降了30.0%。分析师预测,OPKO Health,Inc.本财年每股收益将为0.38美元。

Wall Street Analyst Weigh In

华尔街分析师也加入进来

Separately, Piper Sandler cut their price objective on shares of OPKO Health from $5.00 to $4.00 and set an "overweight" rating on the stock in a report on Friday, August 5th.

另外,派珀·桑德勒将OPKO Health的股票目标价从5.00美元下调至4.00美元,并在8月5日星期五的一份报告中对该股设定了“增持”评级。

Hedge Funds Weigh In On OPKO Health

对冲基金对OPKO健康的看法

Institutional investors and hedge funds have recently bought and sold shares of the company. Verition Fund Management LLC purchased a new stake in shares of OPKO Health during the second quarter valued at $36,000. Centiva Capital LP purchased a new stake in shares of OPKO Health during the second quarter valued at $131,000. Captrust Financial Advisors grew its holdings in shares of OPKO Health by 13.3% during the second quarter. Captrust Financial Advisors now owns 38,847 shares of the biotechnology company's stock valued at $98,000 after buying an additional 4,573 shares during the last quarter. Creative Planning grew its holdings in shares of OPKO Health by 4.6% during the second quarter. Creative Planning now owns 89,210 shares of the biotechnology company's stock valued at $226,000 after buying an additional 3,963 shares during the last quarter. Finally, Occudo Quantitative Strategies LP grew its holdings in shares of OPKO Health by 143.7% during the second quarter. Occudo Quantitative Strategies LP now owns 75,403 shares of the biotechnology company's stock valued at $191,000 after buying an additional 44,460 shares during the last quarter. 27.83% of the stock is owned by hedge funds and other institutional investors.

机构投资者和对冲基金最近买卖了该公司的股票。Verition Fund Management LLC在第二季度购买了OPKO Health的新股份,价值3.6万美元。Centiva Capital LP在第二季度购买了OPKO Health的新股份,价值131,000美元。CapTrust Financial Advisors在第二季度增持了OPKO Health的股票13.3%。CapTrust Financial Advisors现在拥有这家生物技术公司38,847股股票,价值98,000美元,在上个季度又购买了4,573股。在第二季度,创意规划公司持有的OPKO Health股票增加了4.6%。Creative Planning现在持有这家生物技术公司89,210股票,价值226,000美元,上个季度又购买了3,963股。最后,Occudo Quantity Strategy LP在第二季度增持了OPKO Health的股票143.7%。Occudo Quantity Strategy LP现在拥有这家生物技术公司75,403股票,价值19.1万美元,在上个季度又购买了44,460股票。27.83%的股票由对冲基金和其他机构投资者持有。

About OPKO Health

关于OPKO健康

(Get Rating)

(获取评级)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.

Opko Health,Inc.是一家医疗保健公司,在美国、爱尔兰、智利、西班牙、以色列、墨西哥和国际上从事诊断和制药业务。该公司的诊断部门经营着BioReference实验室,该实验室为疾病的检测、诊断、评估、监测和治疗提供实验室测试服务,包括深奥测试、分子诊断、解剖病理学、遗传学、妇女健康以及为医生办公室、诊所、医院、雇主和政府单位提供的矫正保健;以及在护理地点提供血液测试结果的新型诊断仪器系统,以及4KScore前列腺癌测试服务。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on OPKO Health (OPK)
  • Kroger's is Your One-Stop Consumer Staples Stock
  • Adobe Perfects the Art of the Faceplant for Investors
  • Tax Credits are the Incentives in the Inflation Reduction Act
  • Stock Market: 3 Islands Of Strength In A Sea Of Red
  • 3 Banks Worth Considering For Q4
  • 免费获取StockNews.com关于OPKO健康的研究报告(OPK)
  • 克罗格百货是你的一站式消费者史泰博股票
  • Adobe为投资者完善Facebook工厂的艺术
  • 税收抵免是《降低通货膨胀法案》中的激励措施
  • 股市:红海中的三座强国
  • 第四季度值得考虑的3家银行

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.

接受OPKO健康日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对OPKO Health和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发